Xenon Pharmaceuticals Inc. — Director's Dealing 2023

Mar 14, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Xenon Pharmaceuticals Inc. (XENE)
CIK: 0001582313
Period of Report: 2023-03-10

Reporting Person: KENNEY CHRISTOPHER JOHN (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-03-10	Stock Option (Right to Buy)	$34.18	A	120000	Acquired	2033-03-09	Common Shares (120000)	Direct

Footnotes

F1: Vesting 25% on January 1, 2024 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.